Nucor earnings beat by $0.08, revenue fell short of estimates
SAN DIEGO—Kura Oncology, Inc. (NASDAQ:KURA) Chief Commercial Officer Brian T. Powl recently reported the sale of company shares totaling $12,461. According to a filing with the Securities and Exchange Commission, Powl sold 1,583 shares of common stock at an average price of $7.8719 per share on January 28, 2025. The transaction comes amid a challenging period for the company’s stock, which has declined over 62% in the past six months, according to InvestingPro data.
Following the transaction, Powl retains ownership of 59,667 shares in the company. The sale was conducted to cover taxes associated with the vesting of a restricted stock unit (RSU) received by Powl on January 2, 2024. With the company’s next earnings report scheduled for February 20, 2025, InvestingPro data shows Kura maintains a strong liquidity position with a current ratio of 11.47, indicating robust short-term financial health. Subscribers to InvestingPro can access 10 additional key insights about KURA’s financial outlook and valuation metrics.
In other recent news, Kura Oncology, Inc., a pharmaceutical company specializing in cancer treatments, has secured a new headquarters in San Diego, California. The company signed a lease agreement with HCP Life Science REIT, Inc., for approximately 32,512 square feet. The premises will house Kura’s principal executive offices, research and development facilities, and laboratories.
On the personnel front, Kura Oncology has seen significant changes to its executive team. The company confirmed the departure of Stephen Dale, M.D., who served as the Chief Medical (TASE:PMCN) Officer. Following his resignation, Kura Oncology announced the appointment of Mollie Leoni, M.D. as the new Chief Medical Officer, and Francis Burrows, Ph.D. as the new Chief Scientific Officer. These changes come amidst a settlement agreement with Dr. Dale, which includes an 18-month base salary continuation and the payment of his 2024 annual cash bonus.
Kura Oncology has also expanded its stock option plan, reserving an additional 1.9 million shares. This strategic move is aimed at attracting top talent and expanding its workforce. On the financial side, Stifel, a financial services firm, recently adjusted its outlook on Kura Oncology, reducing the price target to $11.00 from the previous $18.00, while maintaining a Hold rating on the stock.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.